Vergleich

c-Kit-IN-3 (hydrochloride)

ArtNr CS-0107041-5mg
Hersteller ChemScene
Menge 5mg
Kategorie
Typ Molecules
Specific against other
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Lieferbar
Purity
>98%
MWt
553.36
Formula
C26H21Cl2F3N2O4
Solubility
10 mM in DMSO
Clinical Information
No Development Reported
Pathway
Protein Tyrosine Kinase/RTK
Target
c-Kit
Biological Activity
c-Kit-IN-3 hydrochloride (Compound 18) is a potent c-KIT kinase inhibitor, which is potent and selective against BaF3-tel-c-KIT (IC50 of 4 nM) and a broad spectrum of drug-resistant mutants (IC50 of 8 nM for BaF3-tel-c-KIT-T670I) with improved bioavailability[1]. IC50 & Target: IC50: 4 nM (BaF3-tel-c-KIT); 8 nM (BaF3-tel-c-KIT-T670I)[1] In Vitro: c-Kit-IN-3 hydrochloride (Compound 18; 0.006 uM-1.37 uM) potently inhibits the growth of c-KIT-dependent GIST cancer cells, such as GIST-T1 (IC50: 0.006 uM); GIST-882 (IC50: 0.013 uM); GIST-T1-T670I (IC50 : 0.011 uM); GIST-5R (IC50: 0.073 uM); GIST-48B (IC50: 1.37 uM), respectively[1].
c-Kit-IN-3 hydrochloride(Compound 18; 0.01-1 uM; 24 hours; GIST-T1, GIST-T1-T670I, and GIST-5R cells) treatment induces dose-dependent cell apoptotic death (by examining the cleaved PARP and cleaved caspase 3)[1].
c-Kit-IN-3 hydrochloride (Compound 18; 0.01-1 uM; 24 hours; GIST-T1, GIST-T1-T670I, and GIST-5R cells) treatment arrests the cell cycle into the G0/G1 phase in all of these three cell lines[1].
c-Kit-IN-3 hydrochloride (Compound 18; 0.1-10 uM; 6 days; primary GIST patient cells) exhibits dose-dependent antiproliferative effects[1].
c-Kit-IN-3 hydrochloride (Compound 18; 0-1 uM; 24 hours) blocks the autophosphorylation of c-KIT pY703, pY719, and pY823 in GIST-T1, GIST-T1-T670I, and GIST-5R, respectively, cells at a concentration of 30 nM and inhibits the downstream signaling mediators pAKT (T308/S473), pS6 (S235/236), and pERK (T202/204)[1].
c-Kit-IN-3 hydrochloride (Compound 18; 0-1 uM; 2 hours) induces dose-dependent cell apoptotic death (by examining the cleaved PARP and cleaved caspase 3) and arrest the cell cycle into the G0/G1 phase in all of these three cell lines[1].
In Vivo: c-Kit-IN-3 hydrochloride (Compound 18; 40-100 mg/kg; oral gavage; daily; for 11 days; for 4 weeks; female BALB/C-nu mice) treatment dose dependently inhibits the BaF3-tel-c-KIT-T670I tumor progression and exhibited almost 100% TGI (tumor growth inhibition) at a dosage of 100 mg/kg/day. And do not affect the animal weights[1].
Research Area
Cancer

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 5mg
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen